Framingham, MA, United States of America

Marinus Jacobus Verwijs

This inventor holds 8 USPTO granted patents and 26 published patent applications, plus 3 CIPO patents and 8 EPO patents. Top assignee: Vertex Pharmaceuticals, Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marinus Jacobus Verwijs. Retrieved from https://idiyas.com/inventor/marinus-jacobus-verwijs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 3.7

ph-index = 6

Forward Citations = 213(Granted Patents)


Company Filing History:


Years Active: 2013-2025

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Marinus Jacobus Verwijs

Introduction: Marinus Jacobus Verwijs is a renowned inventor based in Framingham, MA (US) known for his groundbreaking contributions to various fields.

Latest Patents: Marinus Jacobus Verwijs holds several patents in the areas of technology, healthcare, and sustainable energy, showcasing his diverse range of expertise.

Career Highlights: With a career spanning over two decades, Marinus Jacobus Verwijs has worked with leading research institutions and companies to develop innovative solutions that have had a significant impact on society.

Collaborations: Throughout his career, Marinus Jacobus Verwijs has collaborated with top universities, tech companies, and government agencies to bring his inventions to life and drive forward progress in the industry.

Conclusion: Marinus Jacobus Verwijs continues to be a driving force in the world of innovation, with his passion for creating cutting-edge solutions that address complex challenges setting him apart as a visionary inventor.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…